@US10 silence since XanaHES announcement, page-22

Exactly @bungy234. Also I think that each of us should be just concerned with our own individual investment here & your reasons for investing & trading strategy. They will all be different, some opinions appear to be very shallow, not looking at the bigger picture here.

Whether that is misunderstood or a deliberate misrepresentation, I don’t know, it appears to change day by day, when the FA remains stable.

I hope that recent Investor interview cleared up a few questions, because ACW have the funding & capability to run trials independently if so needed. $8 million in the bank by the end of year & spend winding down at completion of current trials...ready for the next round in AD & other indications. There was no mention of share consolidation.

With data from Xanadu (large international trial) Xanahes cohort 1 @20mg, Target Occupancy & Toxicology studies, there is a huge amount of data in humans here, with proof of cognitive improvement & also crossing the BBB & inhibiting cortisol (Xanadu Trial also). So really, if we are running the next barrage of trials without some form of milestone arrangement with Big Pharma, I will be very surprised, but Actinogen is a well run company that will keep the best interest of drug development, IP & SHs also in mind. I am looking forward to all of this new data on Xanamem & in AD in particular.

One thing mentioned in the recent Investor interview was ACW top 10, they are all still there, including BVF. I think their analysts will have a bit more grey matter onboard than some posters here, with their large investments being accountable.

It’s really nice to see interviewers also get it & say WOW! A lot of Aussie Biotechs fly under the radar until clinical trials get noticed & then, BOOM it happens...out of the Blue (but not really, years in development). GLTAH